Jazz Pharmaceuticals

Revolutionary Cancer Treatment Advances Promise Brighter Future Amid Federal Funding Uncertainty

Retrieved on: 
Friday, September 22, 2023
AMGN, KRAS, Gastrointestinal cancer, Amgen, Optimism, DOR, National Institutes of Health, Bangladesh Technical Education Board, Congress, Patient, Risk, Corr, H. Lee Moffitt Cancer Center & Research Institute, News, Disease, Carcinoma, Oncolytics Biotech, European Hematology Association, Hope, Lung cancer, ONC, Hematology, TSX, Bone marrow, BTC, The Lancet, FDA, Polycythemia, NIH, Safety, Docetaxel, Abstract, Eye, Cancer, NSCLC, PFS, Psoriasis, MD Anderson Cancer Center, Breakthrough therapy, Colorectal cancer, University, Cancer Moonshot, Therapy, ORR, Partnership, CRC, Progression-free survival, RBC Capital Markets, OS, Paclitaxel, SCLC, ASCO, Pelareorep, EHA, Jazz Pharmaceuticals, Breast cancer, Pharmaceutical industry, Birth control, Vaccine, Medical imaging, Protagonist, Research

VANCOUVER, British Columbia, Sept. 22, 2023 /PRNewswire/ -- USA News Group - Despite the potential federal funding challenges due to the recent debt ceiling deal, optimism in the battle against cancer persists, thanks in large part to the audacious "Cancer Moonshot" initiative. This ambitious plan, aimed at halving cancer rates within the next quarter-century, continues to fuel hope even as concerns about the stability of National Institutes of Health (NIH) funding arise. In these turbulent times, the resilience and ingenuity of the biotech sector provide a beacon of hope. For instance, Oncolytics Biotech Inc. (NASDAQ: ONCY) (TSX: ONC), Zymeworks Inc. (NASDAQ: ZYME), Jazz Pharmaceuticals plc (NASDAQ: JAZZ), Protagonist Therapeutics, Inc. (NASDAQ: PTGX), and Amgen Inc. (NASDAQ: AMGN), have each demonstrated inspiring progress and unwavering commitment in advancing cancer treatments, highlighting their vital role in the future of cancer therapy.

Key Points: 
  • The oral presentation shared at the event described how they've been testing a treatment for advanced breast cancer, and it's looking very promising.
  • The treatment combines Oncolytics' flagship drug, pelareorep, with a well-known cancer medicine, paclitaxel.
  • Pelareorep is a unique drug that targets and kills cancer cells by making them self-destruct while leaving healthy cells unharmed.
  • It even lowered the risk of the cancer getting worse by a significant 71% compared to just using paclitaxel.

Revolutionary Cancer Treatment Advances Promise Brighter Future Amid Federal Funding Uncertainty

Retrieved on: 
Friday, September 22, 2023
AMGN, KRAS, Gastrointestinal cancer, Amgen, Optimism, DOR, National Institutes of Health, Bangladesh Technical Education Board, Congress, Patient, Risk, Corr, H. Lee Moffitt Cancer Center & Research Institute, News, Disease, Carcinoma, Oncolytics Biotech, European Hematology Association, Hope, Lung cancer, ONC, Hematology, TSX, Bone marrow, BTC, The Lancet, FDA, Polycythemia, NIH, Safety, Docetaxel, Abstract, Eye, Cancer, NSCLC, PFS, Psoriasis, MD Anderson Cancer Center, Breakthrough therapy, Colorectal cancer, University, Cancer Moonshot, Therapy, ORR, Partnership, CRC, Progression-free survival, RBC Capital Markets, OS, Paclitaxel, SCLC, ASCO, Pelareorep, EHA, Jazz Pharmaceuticals, Breast cancer, Pharmaceutical industry, Birth control, Vaccine, Medical imaging, Protagonist, Research

VANCOUVER, British Columbia, Sept. 22, 2023 /PRNewswire/ -- USA News Group - Despite the potential federal funding challenges due to the recent debt ceiling deal, optimism in the battle against cancer persists, thanks in large part to the audacious "Cancer Moonshot" initiative. This ambitious plan, aimed at halving cancer rates within the next quarter-century, continues to fuel hope even as concerns about the stability of National Institutes of Health (NIH) funding arise. In these turbulent times, the resilience and ingenuity of the biotech sector provide a beacon of hope. For instance, Oncolytics Biotech Inc. (NASDAQ: ONCY) (TSX: ONC), Zymeworks Inc. (NASDAQ: ZYME), Jazz Pharmaceuticals plc (NASDAQ: JAZZ), Protagonist Therapeutics, Inc. (NASDAQ: PTGX), and Amgen Inc. (NASDAQ: AMGN), have each demonstrated inspiring progress and unwavering commitment in advancing cancer treatments, highlighting their vital role in the future of cancer therapy.

Key Points: 
  • The oral presentation shared at the event described how they've been testing a treatment for advanced breast cancer, and it's looking very promising.
  • The treatment combines Oncolytics' flagship drug, pelareorep, with a well-known cancer medicine, paclitaxel.
  • Pelareorep is a unique drug that targets and kills cancer cells by making them self-destruct while leaving healthy cells unharmed.
  • It even lowered the risk of the cancer getting worse by a significant 71% compared to just using paclitaxel.

Jazz Pharmaceuticals to Participate in Three Upcoming Investor Conferences

Retrieved on: 
Wednesday, September 13, 2023
Jazz Pharmaceuticals, PT, IST, Communications satellite

DUBLIN, Sept. 13, 2023 /PRNewswire/ -- Jazz Pharmaceuticals plc (Nasdaq: JAZZ) today announced that Company management will participate in three upcoming investor conferences.

Key Points: 
  • DUBLIN, Sept. 13, 2023 /PRNewswire/ -- Jazz Pharmaceuticals plc (Nasdaq: JAZZ) today announced that Company management will participate in three upcoming investor conferences.
  • Company management will participate in a fireside chat at 12:40 p.m. PT / 3:40 p.m.
  • ET / 8:40 p.m. IST
    Company management will participate in a fireside chat at 9:25 a.m. PT / 12:25 p.m.
  • ET / 6:00 p.m. IST
    Live webcasts, where applicable, may be accessed via the Investors section of the Jazz Pharmaceuticals website at www.jazzpharmaceuticals.com .

Jazz Pharmaceuticals to Participate in Three Upcoming Investor Conferences

Retrieved on: 
Wednesday, September 13, 2023
Jazz Pharmaceuticals, PT, IST, Communications satellite

DUBLIN, Sept. 13, 2023 /PRNewswire/ -- Jazz Pharmaceuticals plc (Nasdaq: JAZZ) today announced that Company management will participate in three upcoming investor conferences.

Key Points: 
  • DUBLIN, Sept. 13, 2023 /PRNewswire/ -- Jazz Pharmaceuticals plc (Nasdaq: JAZZ) today announced that Company management will participate in three upcoming investor conferences.
  • Company management will participate in a fireside chat at 12:40 p.m. PT / 3:40 p.m.
  • ET / 8:40 p.m. IST
    Company management will participate in a fireside chat at 9:25 a.m. PT / 12:25 p.m.
  • ET / 6:00 p.m. IST
    Live webcasts, where applicable, may be accessed via the Investors section of the Jazz Pharmaceuticals website at www.jazzpharmaceuticals.com .

Jazz Pharmaceuticals Announces Key Update to Leadership Team

Retrieved on: 
Tuesday, September 12, 2023
Mathematics, Corcept Therapeutics, Vanderbilt University, Columbia Business School, Eli Lilly, GRAIL, Jazz Pharmaceuticals, Acquisition, Novartis, Patient, CFO, Therapy, Nightclub, Management, Jazz

DUBLIN, Sept. 12, 2023 /PRNewswire/ -- Jazz Pharmaceuticals plc (Nasdaq: JAZZ) today announced that Renée Galá, Chief Financial Officer, has been promoted to President and Chief Operating Officer effective October 1, 2023. Dan Swisher has notified the company of his intention to retire from his position as President and COO after five and a half years of significant contribution towards establishing Jazz as an innovative biopharmaceutical company. Mr. Swisher will continue in a strategic advisor role to assist the Company in an orderly transition through March 2024. The Company will promptly initiate an external search for a Chief Financial Officer.

Key Points: 
  • DUBLIN, Sept. 12, 2023 /PRNewswire/ -- Jazz Pharmaceuticals plc (Nasdaq: JAZZ) today announced that Renée Galá, Chief Financial Officer, has been promoted to President and Chief Operating Officer effective October 1, 2023.
  • Mr. Swisher will continue in a strategic advisor role to assist the Company in an orderly transition through March 2024.
  • I'm excited to welcome Renée to this key role, which is a reflection of her strategic leadership, extensive industry experience and embodiment of Jazz's culture, values and objectives.
  • "It is a privilege to work with such a talented Jazz team that is incredibly passionate, not only about transforming our business, but also the lives of patients and their families," said Renée Galá, Executive Vice President & Chief Financial Officer of Jazz Pharmaceuticals.

Jazz Pharmaceuticals Announces Key Update to Leadership Team

Retrieved on: 
Tuesday, September 12, 2023
Mathematics, Corcept Therapeutics, Vanderbilt University, Columbia Business School, Eli Lilly, GRAIL, Jazz Pharmaceuticals, Acquisition, Novartis, Patient, CFO, Therapy, Nightclub, Management, Jazz

DUBLIN, Sept. 12, 2023 /PRNewswire/ -- Jazz Pharmaceuticals plc (Nasdaq: JAZZ) today announced that Renée Galá, Chief Financial Officer, has been promoted to President and Chief Operating Officer effective October 1, 2023. Dan Swisher has notified the company of his intention to retire from his position as President and COO after five and a half years of significant contribution towards establishing Jazz as an innovative biopharmaceutical company. Mr. Swisher will continue in a strategic advisor role to assist the Company in an orderly transition through March 2024. The Company will promptly initiate an external search for a Chief Financial Officer.

Key Points: 
  • DUBLIN, Sept. 12, 2023 /PRNewswire/ -- Jazz Pharmaceuticals plc (Nasdaq: JAZZ) today announced that Renée Galá, Chief Financial Officer, has been promoted to President and Chief Operating Officer effective October 1, 2023.
  • Mr. Swisher will continue in a strategic advisor role to assist the Company in an orderly transition through March 2024.
  • I'm excited to welcome Renée to this key role, which is a reflection of her strategic leadership, extensive industry experience and embodiment of Jazz's culture, values and objectives.
  • "It is a privilege to work with such a talented Jazz team that is incredibly passionate, not only about transforming our business, but also the lives of patients and their families," said Renée Galá, Executive Vice President & Chief Financial Officer of Jazz Pharmaceuticals.

Jazz Pharmaceuticals Showcases Impact of Sleep Medicine Portfolio at Psych Congress 2023

Retrieved on: 
Monday, September 11, 2023
Psych, Abstract, Abstract (summary), Bachelor of Medicine, Bachelor of Surgery, Narcolepsy, Depression, University, Idiopathic hypersomnia, Magnesium, Anxiety, Safety, Efficacy, Quality of life, Medical school, Research, Mental health, Disruption, Calcium, DSM-IV codes, Literature, Patient, Sleep disorder, Physician, Psychiatry, FCCP, MRCPCH, Jazz Pharmaceuticals, Potassium, Pharmaceutical industry, Sleep, Gamma-Hydroxybutyric acid, MD, Medicine

DUBLIN, Sept. 11, 2023 /PRNewswire/ -- Jazz Pharmaceuticals plc (Nasdaq: JAZZ) today announced that six abstracts presenting data from across its sleep medicine portfolio were featured at the 36th annual Psych Congress, held September 6-10, 2023. One of the accepted abstracts provided a comprehensive review of clinical data that assessed the impact of oxybate on sleep quality, sleep architecture and measures of disrupted nighttime sleep in narcolepsy. Oxybate is the active ingredient in Xywav® (calcium, magnesium, potassium, and sodium oxybates) oral solution.

Key Points: 
  • Review of multiple clinical trials provided a comprehensive analysis showing that oxybate improves sleep quality, sleep architecture and measures of disrupted nighttime sleep in narcolepsy, independent of once- or twice-nightly dosing
    DUBLIN, Sept. 11, 2023 /PRNewswire/ -- Jazz Pharmaceuticals plc (Nasdaq: JAZZ) today announced that six abstracts presenting data from across its sleep medicine portfolio were featured at the 36th annual Psych Congress, held September 6-10, 2023.
  • One of the accepted abstracts provided a comprehensive review of clinical data that assessed the impact of oxybate on sleep quality, sleep architecture and measures of disrupted nighttime sleep in narcolepsy.
  • The review found that oxybate improved measures of sleep architecture and disrupted nighttime sleep in narcolepsy patients, independent of dosing regimen or prior oxybate experience.
  • "Idiopathic hypersomnia has a profound impact on those who live with this debilitating sleep disorder," said Kelvin Tan, MBBCh, MRCPCH, senior vice president and chief medical officer of Jazz Pharmaceuticals.

Jazz Pharmaceuticals Showcases Impact of Sleep Medicine Portfolio at Psych Congress 2023

Retrieved on: 
Monday, September 11, 2023
Psych, Abstract, Abstract (summary), Bachelor of Medicine, Bachelor of Surgery, Narcolepsy, Depression, University, Idiopathic hypersomnia, Magnesium, Anxiety, Safety, Efficacy, Quality of life, Medical school, Research, Mental health, Disruption, Calcium, DSM-IV codes, Literature, Patient, Sleep disorder, Physician, Psychiatry, FCCP, MRCPCH, Jazz Pharmaceuticals, Potassium, Pharmaceutical industry, Sleep, Gamma-Hydroxybutyric acid, MD, Medicine

DUBLIN, Sept. 11, 2023 /PRNewswire/ -- Jazz Pharmaceuticals plc (Nasdaq: JAZZ) today announced that six abstracts presenting data from across its sleep medicine portfolio were featured at the 36th annual Psych Congress, held September 6-10, 2023. One of the accepted abstracts provided a comprehensive review of clinical data that assessed the impact of oxybate on sleep quality, sleep architecture and measures of disrupted nighttime sleep in narcolepsy. Oxybate is the active ingredient in Xywav® (calcium, magnesium, potassium, and sodium oxybates) oral solution.

Key Points: 
  • Review of multiple clinical trials provided a comprehensive analysis showing that oxybate improves sleep quality, sleep architecture and measures of disrupted nighttime sleep in narcolepsy, independent of once- or twice-nightly dosing
    DUBLIN, Sept. 11, 2023 /PRNewswire/ -- Jazz Pharmaceuticals plc (Nasdaq: JAZZ) today announced that six abstracts presenting data from across its sleep medicine portfolio were featured at the 36th annual Psych Congress, held September 6-10, 2023.
  • One of the accepted abstracts provided a comprehensive review of clinical data that assessed the impact of oxybate on sleep quality, sleep architecture and measures of disrupted nighttime sleep in narcolepsy.
  • The review found that oxybate improved measures of sleep architecture and disrupted nighttime sleep in narcolepsy patients, independent of dosing regimen or prior oxybate experience.
  • "Idiopathic hypersomnia has a profound impact on those who live with this debilitating sleep disorder," said Kelvin Tan, MBBCh, MRCPCH, senior vice president and chief medical officer of Jazz Pharmaceuticals.

Allay Therapeutics Appoints Nicole Vitullo to Board of Directors

Retrieved on: 
Wednesday, September 6, 2023
Health, Surgery, Clinical Trials, Research, Science, Pharmaceutical, Biotechnology, Nicole, Actavis, University, Esperion Therapeutics, Transformation/transcription domain-associated protein, MBA, Cubist Pharmaceuticals, Onyx Pharmaceuticals, Esperies, Celgene, Partner, Patient, Forest Laboratories, Arboretum, Pain management, Alexion, Jazz Pharmaceuticals, David Allais, Mathematics, Therapy, Caregiver, Pharmaceutical industry

Allay Therapeutics, a clinical-stage biotechnology company pioneering ultra-sustained analgesic products to transform post-surgical pain management and recuperation, today announced the appointment of Nicole Vitullo, venture partner at Arboretum Ventures, to its board of directors.

Key Points: 
  • Allay Therapeutics, a clinical-stage biotechnology company pioneering ultra-sustained analgesic products to transform post-surgical pain management and recuperation, today announced the appointment of Nicole Vitullo, venture partner at Arboretum Ventures, to its board of directors.
  • “We’re thrilled to have Nicole join the Allay board and appreciate the continued support of Arboretum Ventures as we work to change the pain management paradigm and dramatically improve the post-surgical recovery experience for patients,” said Adam Gridley, Chief Executive Officer of Allay Therapeutics.
  • Nicole currently serves on the board of Esperion Therapeutics and Hinge Bio Inc.
  • Her past board memberships include numerous companies that have entered transactions, including Achillion Pharmaceuticals (Alexion), Calixa Therapeutics (Cubist Pharmaceuticals), Celator Pharmaceuticals (Jazz Pharmaceuticals), Cerexa (Forest Laboratories), Durata Therapeutics (Actavis), Marinus Pharmaceuticals, Onyx Pharmaceuticals, and VentiRx Pharmaceuticals (Celgene).

Jazz Pharmaceuticals to Participate in Citi's 18th Annual BioPharma Conference

Retrieved on: 
Thursday, August 24, 2023
Jazz Pharmaceuticals, Webcast, PT, IST, Conference, Nightclub, Broadcasting

DUBLIN, Aug. 24, 2023 /PRNewswire/ -- Jazz Pharmaceuticals plc (Nasdaq: JAZZ) today announced that the Company will participate in the Citi Annual BioPharma Conference in Boston.

Key Points: 
  • DUBLIN, Aug. 24, 2023 /PRNewswire/ -- Jazz Pharmaceuticals plc (Nasdaq: JAZZ) today announced that the Company will participate in the Citi Annual BioPharma Conference in Boston.
  • Company management will participate in a fireside chat on Thursday, September 7, 2023, at 8:20 a.m. PT / 11:20 a.m.
  • An audio webcast of the presentation will be available via the Investors section of the Jazz Pharmaceuticals website at www.jazzpharmaceuticals.com .
  • A replay of the webcast will be archived on the website for 30 days.